Replies to post #70568 on Biotech Values

[DewDiligence]

>MNTA – I can take a guess that product 4 [M178] is Neulasta and it's also for $10M in milestones. Leaving $168M for C+L.<

If M178 is indeed Neulasta, the $10M figure is probably correct. If it’s Remicade, Enbrel, or something else, the figure might be a little higher.

I haven’t checked the US patent status on Neulasta.

[DewDiligence]

MNTA:

I can take a guess that product 4 [M178] is Neulasta and it's also for $10M in milestones. Leaving $168M for C+L.

We may never know what the drug was, but you were pretty close on the numbers: $163M of potential milestones remain for Copaxone and Lovenox.